Bristol-Myers Squibb Co. (BMY) — Analysis Summary
Bristol-Myers Squibb Co. (BMY) has a market cap of $121.18B with year-over-year revenue growth of -0.2%. Net margin stands at 14.6%. The stock trades at a P/E ratio of 16.7.
Key Takeaways
- Revenue changed -0.2% year-over-year
- Net margin of 14.6%
- P/E ratio of 16.7
Compared to other companies in the PHARMACEUTICAL PREPARATIONS sector, BMY posted revenue growth of -0.2% and trades at a P/E of 16.7.
Bristol-Myers Squibb Co. (BMY)
UPDATED — ET · SOURCE POLYGON
Red Flags & WarningsHigh Risk Signals
Multiple material red flags are active and deserve closer underwriting before relying on any valuation output.
Interest coverage at 0.0x — earnings do not cover interest payments
Bristol Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.
Sector
PHARMACEUTICAL PREPARATIONS
Employees
32,500
Headquarters
PRINCETON, NJ
Exchange
XNYS
Systematic competitive advantage assessment based on 4yr data
This assessment is based on quantitative analysis of historical financial data and does not constitute investment advice. Moat ratings may change with industry and competitive dynamics.
First version surfaces recent SEC Forms 3, 4, and 5 activity. It does not yet parse individual buy/sell transactions.
Capital Structure
Cash Flow
Annual Dividend/Share
$2.52
Dividend Yield
4.42%
Dividend History
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.